Board of Directors

Martin B. Wax, MD

Chairman of the Board

Chief Medical Officer and Executive Vice-President, PanOptica, Inc.

Martin B. Wax, M.D., is chief medical officer and executive vice president of R&D at PanOptica, Inc., a private biotechnology company specializing in ophthalmic pharmaceuticals. He previously served as vice president of R&D and head of discovery research and preclinical sciences at Alcon Laboratories, where he was responsible for the creation and early development of the Alcon pharmaceutical portfolio.

Dr. Wax received his medical degree from the University of Southern California in Los Angeles. He completed his residency in Ophthalmology at Wills Eye Hospital in Pennsylvania, and post-doctoral fellowships in molecular pharmacology and glaucoma at the University of Pennsylvania School of Medicine.

He currently holds an appointment as a Professor of Ophthalmology and Visual Sciences at the University of Texas Southwestern Medical School in Dallas, and has been selected as one of the “Best Doctors in America” by his peers. An internationally recognized scientific expert in the field of glaucoma, Dr. Wax has co-authored more than 200 publications and serves on several scientific advisory committees and editorial boards.

Read More »
Cedric Bisson, MD

Venture Partner, Teralys Capital

Cédric Bisson is venture partner at Teralys Capital where he leads activities in healthcare and life sciences. Teralys Capital is Canada’s largest technology-focused fund of funds financing private venture capital funds that invest in information technology, life sciences and cleantech companies. Until he joined Teralys, Mr. Bisson was managing partner for healthcare at iNovia Capital in Montreal and Calgary, a private venture capital firm aimed at entrepreneurship and company building, during which he also created MSBi Valorisation, a seed technology transfer and investor firm focused principally on McGill University.

Mr. Bisson was previously an associate principal at McKinsey & Company, a global management consulting firm, where he was a leader in the healthcare and innovation practices in Montreal, New York City and Paris.

In his community time, Mr. Bisson serves as chairman of the board of the Biennale de Montréal and chairman of the board of Procure (non-profit charity against prostate cancer). He obtained a M.D. degree from McGill University and a J.D. (law) degree from Universite de Montreal

See More »
Sena Biswas, PhD

Managing Partner, VIMAC Ventures

Sena Biswas is Managing Director, Life Sciences at VIMAC Ventures. He serves on the Boards of Directors of Angiochem, Combinent, Mimetogen, and Neotropix. He was formerly founding President of Merrimack Pharmaceuticals, and interim CEO of ActiveCyte, iCEO, and Combinent Biomedical and has served in operating roles at several of the VIMAC portfolio companies.

Earlier experiences include as a venture capitalist with TL Ventures, Business Development and Strategic Planning with Rhone-Poulenc Rorer Pharmaceuticals, and investment banking with the Healthcare Group currently at JP Morgan.

Mr. Biswas completed a postdoctoral fellowship in molecular immunology at Harvard Medical School, has a PhD in Molecular Biology from the University of Pennylvania, an MBA from the Wharton School and a BA in Biology from Brandeis University.

Go »
Kevin Giese

Mr. Kevin Giese was the founder of BioMS Medical Corp. which company raised over $280 million, and in 2008 was designated Biotech Company of the year in Canada and awarded the Scrips Award for Best International Licensing Deal.

Mr. Giese has been on the board of directors of a number of private and publicly listed companies, including Spectral Diagnostics Inc. since March 2010, and Mimetogen Pharmaceuticals Inc. since October 2011.

He has been a member of the board of directors of BioAlberta, an advisory member of the Institute of Corporate Directors (Canada) and has received awards for entrepreneurship from BioAlberta and Ernst & Young. Mr. Giese has a B.A., a law degree and an M.B.A.

Garth Cumberlidge, PhD

President & CEO, Mimetogen Pharmaceuticals

Garth Cumberlidge has served as the Company’s President, Chief Executive Officer and member of the Board of Directors since September 2005. Dr. Cumberlidge has over 25 years experience in the research products, diagnostics and healthcare industries.

Prior to his joining Mimetogen, he was President & CEO of Qbiogene Inc., where over a period of six years he successfully raised over $50 million in venture funding and grew the company to over $50 million in revenues. Prior to that he held a senior executive position in ICN Pharmaceuticals, as Vice President, Worldwide Marketing & Sales for the ICN Biomedicals portfolio. Prior to that he held senior positions in Sigma Chemicals Company as European Sales & Marketing Manager, based in Munich, Germany, and Worldwide Sales & Marketing Manager based in the United States, with responsibility for the sales and marketing strategy for research immuno-chemicals business.

Dr. Cumberlidge holds a B.Sc. in Biochemistry and Genetics from the University of London (U.K.) and a PhD. in Molecular Genetics from the Max-Planck-Institute for Molecular Genetics, Berlin. (Germany)